These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15258894)

  • 1. Thrombogenic and atherogenic activities of lysophosphatidic acid.
    Siess W; Tigyi G
    J Cell Biochem; 2004 Aug; 92(6):1086-94. PubMed ID: 15258894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques.
    Rother E; Brandl R; Baker DL; Goyal P; Gebhard H; Tigyi G; Siess W
    Circulation; 2003 Aug; 108(6):741-7. PubMed ID: 12885756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors.
    Haserück N; Erl W; Pandey D; Tigyi G; Ohlmann P; Ravanat C; Gachet C; Siess W
    Blood; 2004 Apr; 103(7):2585-92. PubMed ID: 14645014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin.
    Khandoga AL; Fujiwara Y; Goyal P; Pandey D; Tsukahara R; Bolen A; Guo H; Wilke N; Liu J; Valentine WJ; Durgam GG; Miller DD; Jiang G; Prestwich GD; Tigyi G; Siess W
    Platelets; 2008 Sep; 19(6):415-27. PubMed ID: 18925509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate.
    Siess W
    Biochim Biophys Acta; 2002 May; 1582(1-3):204-15. PubMed ID: 12069830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions.
    Siess W; Zangl KJ; Essler M; Bauer M; Brandl R; Corrinth C; Bittman R; Tigyi G; Aepfelbacher M
    Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6931-6. PubMed ID: 10359816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidic acid induces neointima formation through PPARgamma activation.
    Zhang C; Baker DL; Yasuda S; Makarova N; Balazs L; Johnson LR; Marathe GK; McIntyre TM; Xu Y; Prestwich GD; Byun HS; Bittman R; Tigyi G
    J Exp Med; 2004 Mar; 199(6):763-74. PubMed ID: 15007093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysophosphatidic acid is the unique platelet-activating substance in human malignant ascites.
    Sandmann G; Siess W; Essler M
    Eur J Med Res; 2003 Sep; 8(9):397-404. PubMed ID: 14555295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet interaction with bioactive lipids formed by mild oxidation of low-density lipoprotein.
    Siess W
    Pathophysiol Haemost Thromb; 2006; 35(3-4):292-304. PubMed ID: 16877878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role of lysophosphatidic acid in hypertension and atherosclerosis.
    Xu YJ; Aziz OA; Bhugra P; Arneja AS; Mendis MR; Dhalla NS
    Can J Cardiol; 2003 Dec; 19(13):1525-36. PubMed ID: 14760444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway.
    Pamuklar Z; Lee JS; Cheng HY; Panchatcharam M; Steinhubl S; Morris AJ; Charnigo R; Smyth SS
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):555-61. PubMed ID: 18202325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation.
    Subramanian P; Karshovska E; Reinhard P; Megens RT; Zhou Z; Akhtar S; Schumann U; Li X; van Zandvoort M; Ludin C; Weber C; Schober A
    Circ Res; 2010 Jul; 107(1):96-105. PubMed ID: 20360252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPR92/LPA₅ lysophosphatidate receptor mediates megakaryocytic cell shape change induced by human atherosclerotic plaques.
    Khandoga AL; Pandey D; Welsch U; Brandl R; Siess W
    Cardiovasc Res; 2011 Apr; 90(1):157-64. PubMed ID: 21106562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI.
    Penz S; Reininger AJ; Brandl R; Goyal P; Rabie T; Bernlochner I; Rother E; Goetz C; Engelmann B; Smethurst PA; Ouwehand WH; Farndale R; Nieswandt B; Siess W
    FASEB J; 2005 Jun; 19(8):898-909. PubMed ID: 15923400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.
    Cheng Y; Makarova N; Tsukahara R; Guo H; Shuyu E; Farrar P; Balazs L; Zhang C; Tigyi G
    Cell Signal; 2009 Dec; 21(12):1874-84. PubMed ID: 19709640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysophosphatidic acid reduces the organ injury caused by endotoxemia-a role for G-protein-coupled receptors and peroxisome proliferator-activated receptor-gamma.
    Murch O; Collin M; Thiemermann C
    Shock; 2007 Jan; 27(1):48-54. PubMed ID: 17172980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids.
    Tokumura A; Sinomiya J; Kishimoto S; Tanaka T; Kogure K; Sugiura T; Satouchi K; Waku K; Fukuzawa K
    Biochem J; 2002 Aug; 365(Pt 3):617-28. PubMed ID: 11982483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist.
    McIntyre TM; Pontsler AV; Silva AR; St Hilaire A; Xu Y; Hinshaw JC; Zimmerman GA; Hama K; Aoki J; Arai H; Prestwich GD
    Proc Natl Acad Sci U S A; 2003 Jan; 100(1):131-6. PubMed ID: 12502787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
    Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysophosphatidic acid in atherosclerotic diseases.
    Schober A; Siess W
    Br J Pharmacol; 2012 Oct; 167(3):465-82. PubMed ID: 22568609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.